RT journal article T1 In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study A1 Quindós, Guillermo A1 Miranda-Cadena, Katherine A1 San-Millán, Rosario A1 Borroto-Esoda, Katyna A1 Cantón, Emilia A1 Linares-Sicilia, María José A1 Hamprecht, Axel A1 Montesinos, Isabel A1 Tortorano, Anna M. A1 Prigitano, Anna A1 Vidal-García, Matxalen A1 Marcos-Arias, Cristina A1 Guridi, Andrea A1 Sánchez-Reus, Ferrán A1 Machuca Bárcena, Jesús A1 Rodríguez Iglesias, Manuel Antonio A1 Martín-Mazuelos, Estrella A1 Castro-Méndez, Carmen A1 López-Soria, Leyre A1 Ruiz-Gaitán, Alba A1 Fernández-Rivero, Marcelo A1 Lorenzo, Damaris A1 Capilla, Javier A1 Rezusta, Antonio A1 Pemán, Javier A1 Guarro, Josep A1 Pereira, Joana A1 Pais, Célia A1 Romeo, Orazio A1 Ezpeleta, Guillermo A1 Jauregizar, Nerea A1 Angulo, David A1 Eraso, Elena A2 BiomedicinaBiotecnología y Salud Pública K1 antifungal testing K1 antifungal resistance K1 Candida K1 ibrexafungerp K1 SCY-078 K1 EUCAST K1 caspofungin K1 micafungin AB BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. MethodsIbrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. ResultsIbrexafungerp MICs ranged from 0.016 to >= 8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06->= 8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. ConclusionIbrexafungerp showed a potent in vitro activity against Candida. PB FRONTIERS MEDIA SA SN 2235-2988 YR 2022 FD 2022-05 LK http://hdl.handle.net/10498/27708 UL http://hdl.handle.net/10498/27708 LA eng DS Repositorio Institucional de la Universidad de Cádiz RD 17-nov-2026